This study is looking at the long-term safety and how well inhaled treprostinil works for people with Idiopathic Pulmonary Fibrosis (IPF) or Progressive Pulmonary Fibrosis (PPF). Inhaled treprostinil is a drug delivered as a mist you breathe in, using a special device. To join this study, you must have already participated in one of three specific previous studies (RIN-PF-301, RIN-PF-303, or RIN-PF-305). Researchers will be monitoring your health and lung function over time to see if the treatment is safe and tolerable. The study is currently unclear on its recruitment status and plans to enroll up to 1850 participants.

Study design

This is a Phase 3, multicenter, open-label extension study. It is designed for participants who completed previous studies.

What's involved

You would return for visits at Week 4, Week 12, and then every 12 weeks for up to 6 years. These visits will include tests like spirometry (a breathing test) and monitoring for side effects.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 6 years to assess long-term safety and tolerability.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.